Allogene Therapeutics, Inc. Common Stock
Here’s whether Allogene Therapeutics, Inc. Common Stock (ALLO) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); RSI 45 — healthy momentum range; strong 1-year return of +35.7%. Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-3.32% over 10 days); 3-month momentum negative (-22.1%). Currently 57.4% off its 52-week high. Score: +1/7.
ALLO is holding above its long-term 200-day MA ($1.74) but has slipped below the 50-day MA ($2.22), pointing to short-term weakness in an otherwise intact trend. An RSI of 44.6 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +35.7% compares to +22.9% for SPY (beat the market by 12.8%). The current 57.4% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.